Who: GlaxoSmithKline
With: Brazil
What: $2.2 billion deal
Summary: In a move designed to help bolster Brazil's emerging drug market (and GSK's emerging market plans), Glaxo inked a $2.2 billion deal to supply its Synflorix vaccine to Brazil. But the GSK/Brazil 10-year contract wasn't simply a vaccine supply deal. It included a provision through which the price of Synflorix will fall from about $17 to a little more than $7 per dose over time, as well as a technology transfer component. Over the course of the contract, GSK will pass on the knowledge and expertise necessary to help Brazil make its own vaccine. Plus, Glaxo will invest €35 million ($51 million) into an effort to develop a dengue fever vaccine, matching Brazil's own investment into the effort.
Links:
[1] http://www.fiercebiotech.com/special-reports/bms-and-medarex-top-10-deals-2009
[2] http://www.fiercebiotech.com/special-reports/top-10-biopharma-deals-2009
[3] http://www.fiercebiotech.com/special-reports/roche-and-ptc-therapeutics-top-10-deals-2009